醫(yī)療特長:
專注于神經(jīng)內(nèi)分泌腫瘤綜合治療,,原發(fā)性肝癌等惡性腫瘤微創(chuàng)介入治療(介入化療栓塞術(shù),、消融、粒子植入,、靶向藥物治療及免疫治療等)
研究方向:
神經(jīng)內(nèi)分泌腫瘤綜合治療臨床及基礎(chǔ)研究,、肝臟疾患功能影像學(xué)及分子機制研究、肝臟惡性腫瘤介入及姑息治療臨床及分子機制研究,、精索靜脈曲張及骨關(guān)節(jié)炎等良性疾病的診治,。主持多項國家自然科學(xué)基金及省部級基金課題,以第一作者或通訊作者身份在Oncogene,、Neuroendocrinology,、CVIR、BMC Cancer等SCI期刊發(fā)表高質(zhì)量論著數(shù)十篇,。作為唯一介入專家參與撰寫《中國胰腺神經(jīng)內(nèi)分泌腫瘤診療指南》,、《胃腸胰神經(jīng)內(nèi)分泌腫瘤診治專家共識(2020)》。
主要教育和工作經(jīng)歷:
1999年畢業(yè)于中山醫(yī)科大學(xué)臨床醫(yī)學(xué)專業(yè),,留校工作,。2008年獲中山大學(xué)臨床醫(yī)學(xué)博士學(xué)位。2020年12月評聘主任醫(yī)師,。
社會兼職:
廣東省抗癌協(xié)會腫瘤微創(chuàng)介入專業(yè)委員會青年委員會副主任委員
廣東省抗癌協(xié)會膽道腫瘤專業(yè)委員會青年委員會副主任委員
中華醫(yī)學(xué)會消化病學(xué)分會第十一屆委員會胃腸激素與神經(jīng)內(nèi)分泌腫瘤學(xué)組委員
中國抗癌協(xié)會胰腺癌專業(yè)委員會神經(jīng)內(nèi)分泌腫瘤學(xué)組委員
中國醫(yī)師協(xié)會胰腺病學(xué)專業(yè)委員會胰腺神經(jīng)內(nèi)分泌腫瘤專業(yè)委員會委員
中國研究型醫(yī)院學(xué)會消化外科專業(yè)委員會神經(jīng)內(nèi)分泌腫瘤學(xué)組委員
廣東省肝臟病學(xué)會綜合治療專業(yè)委員會常委
廣東省臨床醫(yī)學(xué)學(xué)會腫瘤介入學(xué)專業(yè)委員會常委兼秘書
論著:
- Liu Y, Chen W, Cui W, Liu H, Zhou X, Chen L, Li J, Chen M, Chen J, Wang Y(corresponding author). Quantitative Pretreatment CT Parameters as Predictors of Tumor Response of NET Liver Metastasis to TAE. Neuroendocrinology. 2019 Oct 22;10.1159/000504257. doi: 10.1159/000504257. [Epub ahead of print]. PMID: 31639795.
- Lian F, Chen W, Liu Y, Shen L, Fan W, Cui W, Zhao Y, Li J, Wang Y(corresponding author). Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer. J Cancer Res Clin Oncol. 2019 Mar 21. doi: 10.1007/s00432-019-02900-8. [Epub ahead of print].
- Cui W, Fan W, Lu M, Zhang Y, Yao W, Li J, Wang Y(corresponding author). The safety and efficacy of percutaneous intraductal radiofrequency ablation in unresectable malignant biliary obstruction: A single-institution experience. BMC Cancer. 2017 Apr 24;17(1):288. doi: 10.1186/s12885-017-3278-5.
- Wang Y, Lian F, Li J, Fan W, Xu H, Yang X, Liang L, Chen W, Yang J. Adipose derived mesenchymal stem cells transplantation via portal vein improves microcirculation and ameliorates liver fibrosis induced by CCl4 in rats. Journal of Translational Medicine. 2012, 10(1): 133.
- Lian F, Wang Y(corresponding author), Chen W, Li J, Zhan Z, Ye Y, Zhu Y, Huang J, Xu H, Yang X, Liang L, Yang J. Uterine Artery Embolization Combined with Local Methotrexate and Systemic Methotrexate for Treatment of Cesarean Scar Pregnancy with Different Ultrasonographic Pattern. Cardiovasc Intervent Radiol. 2012; 35(2): 286-91.
- 王于,,李家平,,楊建勇,。膽腸吻合口狹窄的介入治療。中國實用外科雜志,。2014,,34(10):945-947.
- 范文哲,翁慧雯,,姚學(xué)華,,張應(yīng)強,王于(通訊作者),。經(jīng)肝動脈栓塞化療聯(lián)合125I粒子治療肝細(xì)胞癌的Meta分析,。消化腫瘤雜志(電子版)。2013,,5(2):114-118.
- 劉一銘, 連帆, 周翔飛, 陳文川, 劉海寬, 姚望, 范文哲, 李家平, 陳潔, 王于(通訊作者),。 肝動脈栓塞術(shù)聯(lián)合長效奧曲肽降低中低級別神經(jīng)內(nèi)分泌瘤肝轉(zhuǎn)移負(fù)荷的療效及安全性分析,。中華醫(yī)學(xué)雜志,2019,99(15):1142-1146,。
- 申龍, 連帆, 范文哲, 劉一銘, 李家平, 王于(通訊作者),。非肌層浸潤性膀胱癌TURBT術(shù)后髂內(nèi)動脈灌注化學(xué)治療療效的影響因素分析。新醫(yī)學(xué),,2018,49(2),,99-104。
國際會議論文摘登
1. Percutaneous intraductal RFA plus metal stents implantation in the management of malignant bilioenteric anastomose stricture post choledochojejunostomy. CIRSE 2017, P-18
2. TAE combined with systemic Octreotide LAR treatment alleviated the Type III liver metastases burden of p-NET significantly and rapidly. CIRSE 2017, P-114.
3. Transcatheter Arterial Chemoembolization combined with Sorafenib for unresectable recurrent hepatocellular carcinoma: a retrospectively study. ECR 2018, P-923
4. The multiple intrahepatic recurrence after curative resection of hepatocellular carcinoma treated with sequential Transcatheter arterial chemoembolization (TACE) and Radiofrequency ablation (RFA) versus TACE alone: A retrospective study. ECR 2018, P-805.
5. Therapeutic effect of adipose tissue-derived mesenchymal stem cells transplantation for cirrhosis rats. Cardiovasc Intervent Radiol. CIRSE09. Abstract.
6. “Rookie wall”, a phenomenon commonly seen but usually overlooked among junior interventional radiologists. Abstract ID 80722. CIRSE 2019.
7. Neutrophil lymphocyte ratio: a kind of response predictors of neuroendocrine tumor liver metastasis treated by transcatheter arterial embolization. Abstract ID 80461.CIRSE 2019.
8. Expression of VEGFR as response predictors of neuroendocrine tumor liver metastasis (NETLM) treated by transcatheter arterial embolization (TAE). Abstract ID 80657. CIRSE 2019.
9. Bland microspheres embolism plus SSA system therapy: safety and efficiency for massive tumor burden over 75% of neuroendocrine tumors liver metastasis (NETLM). Abstract ID 79172. CIRSE 2019.
10. Parameters on 18F-FDG-PET/CT as response predictors of neuroendocrine tumor liver metastasis (NETLM) treated by transcatheter arterial embolization (TAE). Abstract ID 80034. CIRSE 2019.
專著:
其他主要工作成績(比如獲獎情況):
2020年度:羊城好醫(yī)生,。